ZYVERSA THERAPEUTICS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Increase (Decrease) in Prepaid Expense and Other Assets of $92.37 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-05-13
- ZYVERSA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $92.37K, a 70.57% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$66.55K.
- ZYVERSA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$80.56K.
- ZYVERSA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-06-30 was -$120.03K.
- ZYVERSA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $46.77K.
- ZYVERSA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$30.59K.
- ZYVERSA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$56.55K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 1 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 11 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $92.37K 10-Q · filed 2026-05-13 | $25.82K derived: sum of 2 quarters · filed 2026-05-13 | -$54.74K derived: sum of 3 quarters · filed 2026-05-13 | -$174.76K derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2025-12-31 | -$66.55K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$147.11K derived: sum of 2 quarters · filed 2026-03-31 | -$267.14K derived: sum of 3 quarters · filed 2026-03-31 | $46.77K 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | -$80.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | -$200.59K derived: sum of 2 quarters · filed 2025-11-19 | $113.32K 10-Q · filed 2025-11-19 | $30.70K derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2025-06-30 | -$120.03K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $193.88K 10-Q · filed 2025-08-13 | $111.25K derived: sum of 3 quarters · filed 2026-05-13 | -$143.16K derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2025-03-31 | $313.90K 10-Q · filed 2026-05-13 | $231.28K derived: sum of 2 quarters · filed 2026-05-13 | -$23.13K derived: sum of 3 quarters · filed 2026-05-13 | -$367.70K derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | -$82.62K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$337.03K derived: sum of 2 quarters · filed 2026-03-31 | -$681.60K derived: sum of 3 quarters · filed 2026-03-31 | -$30.59K 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | -$254.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | -$598.98K derived: sum of 2 quarters · filed 2025-11-19 | $52.03K 10-Q · filed 2025-11-19 | -$205.68K derived: sum of 4 quarters · filed 2025-11-19 | ||||
| 2024-06-30 | -$344.57K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $306.45K 10-Q · filed 2025-08-13 | $48.73K derived: sum of 3 quarters · filed 2025-08-13 | -$411.66K derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $651.02K 10-Q · filed 2025-05-12 | $393.30K derived: sum of 2 quarters · filed 2025-05-12 | -$67.09K derived: sum of 3 quarters · filed 2025-05-12 | -$501.73K derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | -$257.72K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$718.11K derived: sum of 2 quarters · filed 2025-03-27 | -$1.15M derived: sum of 3 quarters · filed 2025-03-27 | -$56.55K 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | -$460.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$895.03K derived: sum of 2 quarters · filed 2024-11-14 | $201.17K 10-Q · filed 2024-11-14 | |||||
| 2023-06-30 | -$434.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $661.56K 10-Q · filed 2024-08-09 | $661.57K 10-Q · filed 2023-08-21 | |||||
| 2023-03-31 | $1.10M 10-Q · filed 2024-05-15 | $701.00K 10-Q · filed 2023-05-12 | ||||||
| 2022-12-31 | -$36.61K 10-K · filed 2024-03-25 | |||||||
| 2022-12-12 | -$73.67K 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |